HC Wainwright Reaffirms 'Buy' Rating for Voyager Therapeutics with Target Price of $30.00

Summary

HC Wainwright reiterated a ‘buy’ rating for Voyager Therapeutics (NASDAQ: VYGR), setting a target price of $30.00. The stock has received multiple ratings, including eight buy ratings and one strong buy rating. Currently, VYGR trades at $2.95, with a market cap of $162.58 million. The company reported a quarterly loss per share of ($0.59), missing expectations. Insider trading showed CEO Alfred Sandrock selling shares, reducing his stake by 2.46%. Institutional investors hold 48.03% of the stock, with recent increases in holdings by major investors.Market Beat

Impact Analysis

The event is at the company level, focusing on Voyager Therapeutics. HC Wainwright’s reaffirmed ‘buy’ rating despite the company missing earnings expectations suggests confidence in future potential, possibly driven by pipeline developments or strategic shifts. The target price implies substantial upside from the current trading price, highlighting investment opportunities. Insider selling by the CEO and missed earnings may present risks, indicating potential internal concerns or financial challenges. However, the increase in institutional holdings could mitigate these risks, reflecting institutional investor confidence. Overall, the rating and target price suggest that Voyager Therapeutics may be undervalued, presenting a high-risk, high-reward scenario for investors.Market Beat